Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCVerso 2: Deleobuvir + Faldaprevir + Ribavirin in HCV GT1b
NCT01728324Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of deleobuvir in hepatitis C (HCV) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Sustained Virologic Response 12 Weeks Post-Treatment. Started Nov 2012; status: completed.
02
Drugs
deleobuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01728324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01728324.